New instrument for automated biorelevant biphasic dissolution and solubility testing
23 October 2013 | By Sirius Analytical Instruments Ltd
Sirius Analytical Instruments Ltd announces the launch of a new product, the Sirius InForm...
List view / Grid view
News
Allergan’s VISTABEL® (botulinum toxin type A) Receives Europe’s First Positive Opinion for Treatment of Moderate to Severe Lateral Canthal Lines (Crow’s Feet Lines) in Adult Patients
23 October 2013 | By Chandler Chicco Agency
Positive opinion paves the way for a second aesthetic indication for VISTABEL® in 29 European countries...
Novartis delivers strong sales performance in third quarter driven by growth products’ momentum; innovation newsflow reinforces growth prospects
22 October 2013 | By Novartis
"Novartis delivered strong sales performance in the third quarter, with all divisions contributing to growth..."
AstraZeneca initiates phase III clinical programme for selumetinib, a treatment in development for patients with non-small-cell lung cancer
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
OGT strengthens focus on cancer biomarkers with appointment of Dr Bob Holland as CMO
21 October 2013 | By College Hill
Dr Holland is an expert in biomarker-driven drug development...
Rigaku Raman Technologies introduces integral fiber optic probe accessories for handheld raman analyzers
21 October 2013 | By Rigaku Raman Technologies
The new Raman Probe II and Economy Probe will enable customers to significantly improve routine laboratory Raman spectroscopy...
DrugDev and CFS Clinical come together to drive clinical trial standards for investigators, CROs and sponsors
21 October 2013 | By Sagefrog Marketing Group, LLC
In the immediate term, the combined capabilities create a powerful offering in finding, engaging and paying Investigators...
IDT Biologika and Oncotec Pharma Produktion announce vaccine and oncology capacity expansion projects
21 October 2013 | By IDT Biologika
IDT Biologika GmbH, a major developer of pharmaceutical technology and a producer of proprietary and third-party biopharmaceuticals and viral and bacterial vaccines, and Oncotec Pharma Produktion announced investments dedicated to increasing their respective production capacities.
Penn Pharma showcases new facility at CPhI World-Wide
18 October 2013 | By Penn Pharma
Penn Pharma will be meeting with professionals at the world’s leading pharmaceutical networking event, CPhI/ICSE World-Wide, from 22nd October – 24th October in Frankfurt...
Former FDA commissioner, Dr. Mark B. McClellan, to join Johnson & Johnson Board of Directors
18 October 2013 | By Johnson & Johnson
Dr. McClellan has more than two decades of public service and academic research experience...
Pfizer reports top-line results from two Lyrica® capsules CV phase 3b studies
The study met its primary endpoint, showing a statistically significant greater reduction in fibromyalgia pain...
GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
18 October 2013 | By GlaxoSmithKline
The application is based primarily on results from an international, multi-centre, randomised Phase III study of ofatumumab...
New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries
18 October 2013 | By Boehringer Ingelheim
"The improvements in lung function and quality of life seen with once-daily Striverdi® Respimat® are remarkable..."
New study demonstrates importance of oral nutritional supplements in helping hospitals achieve medicare readmission reduction requirements
18 October 2013 | By Abbott
One in five Medicare patients is readmitted to a hospital each year at an estimated cost of $17.5 billion annually...
Pfizer receives european approval for label update regarding the use of Prevenar 13 in certain high-risk populations
17 October 2013 | By Pfizer
Label now includes information on use of Prevenar 13 in preterm infants, children and adolescents with sickle cell disease...
